Expression of CCR3 and its ligands in CTCL
| No. . | Diagnosis . | CD30 . | CCR3 . | CCR4 . | CCR8 . | Eotaxin . | MCP-3 . | RANTES . | Eos . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Large-cell CTCL | +++ | ++ | +/− | +/− | pos/TC | neg | pos/TC | pos |
| 2 | Large-cell CTCL | ++ | ++ | ++++ | − | pos/TC + CT | neg | pos/TC | pos |
| 3 | Large-cell CTCL | + | +/− | − | − | pos/TC + CT | neg | neg | pos |
| 4 | Large-cell CTCL | ++++ | ++ | ++ | − | pos/TC | neg | neg | ND |
| 5 | Large-cell CTCL | +++ | ++ | − | − | pos/TC + CT | neg | neg | ND |
| 6 | Large-cell CTCL | + | + | − | +/− | pos/TC + CT | neg | neg | pos |
| 7 | Large-cell CTCL | ++++ | +++ | +++ | − | pos/TC | pos/TC | pos/TC | ND |
| 8 | Large-cell CTCL | ++ | +++ | ++ | − | pos/TC + CT | neg | pos/TC | pos |
| 9 | MF | − | +/− | +++ | − | pos/CT | neg | neg | neg |
| 10 | MF | − | − | − | − | pos/CT | neg | neg | neg |
| 11 | MF | − | − | − | − | pos/TC + CT | neg | neg | pos |
| 12 | MF | − | +/− | − | − | ND | ND | ND | neg |
| 13 | MF | − | − | − | − | pos/CT | neg | neg | pos |
| 14 | MF | +/− | +/− | − | − | pos/CT | neg | neg | neg |
| 15 | Sézary syndrome | − | − | ND | ND | pos/CT | neg | neg | neg |
| 16 | Sézary syndrome | − | − | ND | ND | ND | ND | ND | neg |
| 17 | Sézary syndrome | + | +/− | − | − | pos/CT | neg | neg | neg |
| 18 | Sézary syndrome | − | − | − | − | neg | neg | neg | neg |
| 19 | Sézary syndrome | +/− | +/− | − | − | ND | ND | ND | neg |
| 20 | Sézary syndrome | − | − | ++ | − | pos/CT | neg | neg | pos |
| No. . | Diagnosis . | CD30 . | CCR3 . | CCR4 . | CCR8 . | Eotaxin . | MCP-3 . | RANTES . | Eos . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Large-cell CTCL | +++ | ++ | +/− | +/− | pos/TC | neg | pos/TC | pos |
| 2 | Large-cell CTCL | ++ | ++ | ++++ | − | pos/TC + CT | neg | pos/TC | pos |
| 3 | Large-cell CTCL | + | +/− | − | − | pos/TC + CT | neg | neg | pos |
| 4 | Large-cell CTCL | ++++ | ++ | ++ | − | pos/TC | neg | neg | ND |
| 5 | Large-cell CTCL | +++ | ++ | − | − | pos/TC + CT | neg | neg | ND |
| 6 | Large-cell CTCL | + | + | − | +/− | pos/TC + CT | neg | neg | pos |
| 7 | Large-cell CTCL | ++++ | +++ | +++ | − | pos/TC | pos/TC | pos/TC | ND |
| 8 | Large-cell CTCL | ++ | +++ | ++ | − | pos/TC + CT | neg | pos/TC | pos |
| 9 | MF | − | +/− | +++ | − | pos/CT | neg | neg | neg |
| 10 | MF | − | − | − | − | pos/CT | neg | neg | neg |
| 11 | MF | − | − | − | − | pos/TC + CT | neg | neg | pos |
| 12 | MF | − | +/− | − | − | ND | ND | ND | neg |
| 13 | MF | − | − | − | − | pos/CT | neg | neg | pos |
| 14 | MF | +/− | +/− | − | − | pos/CT | neg | neg | neg |
| 15 | Sézary syndrome | − | − | ND | ND | pos/CT | neg | neg | neg |
| 16 | Sézary syndrome | − | − | ND | ND | ND | ND | ND | neg |
| 17 | Sézary syndrome | + | +/− | − | − | pos/CT | neg | neg | neg |
| 18 | Sézary syndrome | − | − | − | − | neg | neg | neg | neg |
| 19 | Sézary syndrome | +/− | +/− | − | − | ND | ND | ND | neg |
| 20 | Sézary syndrome | − | − | ++ | − | pos/CT | neg | neg | pos |
Staining of different subtypes of cutaneous T-cell lymphoma for CD30, CCR3, CCR4, CCR8, and its ligands eotaxin, MCP-3/CCL7, and RANTES/CCL5. Positive mononuclear cells were counted per high-power field (magnification × 200) on 100 mononuclear cells, and the percentage of positive staining cells was determined as follows: +/− indicates 0% to 5%; +, 5% to 25%; ++, 25% to 50%; +++, 50% to 75%; and ++++, 75% to 100% positive cells. Please note that CCR3 expression corresponds to CD30 expression. Staining for CCR3 ligands shows positivity for eotaxin in CD30+ and CD30− CTCL. Please note that tumor cells and connective tissue cells in CD30+ CTCL are positive for eotaxin, while in CD30− CTCL tumor cell clusters are negative for eotaxin.
Eos indicates eosinophils; pos, positive staining; TC, tumor cells; neg, negative staining; CT, connective tissue cells; ND, not done; and MF, Mycosis fungoides.